1.
Am J Obstet Gynecol MFM
; 5(1): 100761, 2023 01.
Article
in English
| MEDLINE
| ID: mdl-36191892
Subject(s)
COVID-19 , Pregnancy Outcome , Female , Pregnancy , Humans , COVID-19/epidemiology , Immunotherapy , Antibodies, Monoclonal/adverse effects
2.
Open Forum Infect Dis
; 8(7): ofab305, 2021 Jul.
Article
in English
| MEDLINE
| ID: mdl-34258324
ABSTRACT
Bamlanivimab, a monoclonal antibody targeting the spike protein of severe acute respiratory syndrome coronavirus 2, is available for ambulatory treatment of coronavirus disease 2019 (COVID-19). This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency department visits among high-risk outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved mortality.
